RxSight chief business development officer Eric Weinberg sells $14,205 in stock

RxSight's Chief Business Development Officer, Eric Weinberg, recently sold 2,041 shares of the company's common stock for a total value of $14,205. The sale occurred on September 2, 2026, at a price of $6.96 per share, which was specifically to cover tax withholding obligations related to the vesting of restricted stock units. This was not a discretionary sale by Mr. Weinberg.

Despite the current trading price of $7.03, down 32.5% year-to-date, RxSight maintains more cash than debt on its balance sheet. InvestingPro analysis suggests the stock may be undervalued at current levels. Prior to this sale, Weinberg had acquired 5,370 shares on August 31, 2026, upon the vesting of RSUs, with an acquisition price of $0 per share.

These RSUs vest over time, subject to continued service. Mr. Weinberg now directly owns a total of 200,348 shares of RxSight common stock, including shares from the 2021 Employee Stock Purchase Plan and through an EJW Living Trust. RxSight reported second-quarter 2026 results that surpassed expectations, with an adjusted earnings loss of $0.11 per share and revenue of $33.74 million.

However, the company withdrew its full-year guidance due to ongoing challenges in its core business, leading to a decrease in after-hours trading. Stifel adjusted its price target for RxSight to $7.00, maintaining a Hold rating, citing competitive pressures.